"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Scientists in China have demonstrated a new kind of antidepressant could ... are hard to draw conclusions from. In 2022, the antidepressant drug sertraline (another seratonin re-uptake inhibitor ...

Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...

There has been a new antidepressant on the market every two ... This was the fastest acceptance ever for a psychiatric drug. And because it seemed to go beyond treating illness and actually ...

Federal regulators have just given the green light to a second new kind of antidepressant this month, after decades of little progress combating the disease. The US Food and Drug Administration on ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to ...